Form 4: Marimed COO Timothy Shaw Reports Stock Transactions

Marimed Inc.'s Chief Operating Officer, Timothy Shaw, reported the acquisition of 65,000 common shares from RSU conversion and the disposition of 22,523 shares for tax withholding.

Summary

• Timothy Shaw, Chief Operating Officer of Marimed Inc. (MRMD), reported transactions on March 1, 2026.
• Acquired 65,000 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Disposed of 22,523 shares of common stock to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Shaw directly beneficially owns 9,337,018 shares of common stock.
• Additionally, 2,000,000 shares are indirectly owned by the Shaw Family Trust, for which Shaw disclaims beneficial ownership.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation. The vesting of RSUs is a positive for the executive, and the subsequent tax withholding is standard practice. It doesn't indicate any significant operational or financial changes for Marimed Inc.

Positives

• Conversion of 65,000 Restricted Stock Units (RSUs) into common stock indicates vesting and a long-term incentive for the COO.
• The COO continues to hold a significant direct beneficial ownership of 9,337,018 shares, demonstrating alignment with shareholder interests.

Negatives

• Disposition of 22,523 shares for tax withholding reduces the direct beneficial ownership, although this is a standard practice for RSU vesting.

Future Outlook

Remaining Restricted Stock Units (RSUs) from the September 1, 2023 grant are scheduled to vest on September 1, 2026, in accordance with the terms of an award agreement.

Management Comments

• Timothy Shaw disclaims beneficial ownership of the 2,000,000 shares held by the Shaw Family Trust, stating that the filing is not an admission of beneficial ownership for purposes of Section 16 or for any other purpose.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 provide transparency into executive stock ownership and compensation, which can be a signal of management's confidence in the company's future. While this specific filing details routine RSU vesting and tax-related dispositions, it contributes to the overall picture of executive alignment with shareholder interests in the cannabis industry, where Marimed operates.

Comparison to Industry Standards

• The RSU vesting and subsequent tax withholding are standard practices for executive compensation across various industries, including the cannabis sector where Marimed operates. This type of transaction is a common mechanism for executives to realize value from long-term incentive plans.

Related Party Transactions

• Timothy Shaw's spouse is the trustee of the Shaw Family Trust, which holds 2,000,000 shares for the benefit of their children. Shaw disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock ownership and compensation, potentially reinforcing confidence in management's alignment with long-term company performance.
• Employees (specifically Timothy Shaw): Realization of value from long-term incentive compensation (RSUs).

Next Steps

• Remaining Restricted Stock Units (RSUs) from the September 1, 2023 grant are scheduled to vest on September 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax-related share disposition. It does not provide new material information about Marimed Inc.'s operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The significant direct and indirect holdings of the COO remain largely consistent, suggesting continued alignment but no immediate catalyst for a 'buy' or 'sell' decision based solely on this report.

Keywords

Marimed Inc., MRMD, Timothy Shaw, COO, Form 4, Insider Trading, RSU, Restricted Stock Units, Common Stock, Share Ownership, Executive Compensation